Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.97, $0.30 better than the analyst estimate of $0.67. Revenue for the quarter came in at $160.3 million versus the consensus estimate of $147.83 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.